scispace - formally typeset
H

Heike L. Pahl

Researcher at University Medical Center Freiburg

Publications -  142
Citations -  11979

Heike L. Pahl is an academic researcher from University Medical Center Freiburg. The author has contributed to research in topics: Polycythemia vera & Transcription factor. The author has an hindex of 41, co-authored 140 publications receiving 11329 citations. Previous affiliations of Heike L. Pahl include University of Freiburg.

Papers
More filters
Journal ArticleDOI

Activators and target genes of Rel/NF-kappaB transcription factors.

TL;DR: It is argued that NF-κB functions more generally as a central regulator of stress responses and pairing stress responsiveness and anti-apoptotic pathways through the use of a common transcription factor may result in increased cell survival following stress insults.
Journal ArticleDOI

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli.

TL;DR: The data suggest that such diverse stimuli as OA, TNF and PMA use the same kinase system to phosphorylate and thereby destabilize I kappa B‐alpha, leading to NF‐kappa B activation.
Journal ArticleDOI

Tyrosine Phosphorylation of IκB-α Activates NF-κB without Proteolytic Degradation of IκB-α

TL;DR: In this article, the authors reported an alternative mechanism of NF-κB activation by using tyrosine-phosphorylation of IκB-α in the presence of pervanadate.
Journal ArticleDOI

A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B.

TL;DR: It is shown that internal stress, caused by the accumulation of proteins in the endoplasmic reticulum, also induces NF‐kappa B DNA binding as well as kappa B‐dependent gene expression and participates in a novel ER‐nuclear signal transduction pathway distinct from the unfolded‐protein‐response described previously.
Journal ArticleDOI

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

TL;DR: It is reported here that JAK2V617F-associated disease is strongly associated with a specific constitutional Jak2 haplotype, designated 46/1, in all three disease entities compared to healthy controls and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation.